Keyword: Celgene

BMS CEO Giovanni Caforio's pay dipped slightly to $18.8 million last year, as his incentives were tied to the successful integration of Celgene.

Now that ozanimod has finally reached the finish line, it will face a range of challenges, starting with a delayed launch due to COVID-19.

BMS' Empliciti debuted the same month as Darzalex, but it hasn’t followed the J&J drug to stardom. Its latest hurdle? A flopped phase 3 trial.

Sales of Bristol Myers-Squibb’s cancer blockbuster Opdivo fell 2% in the fourth quarter, products picked up from Celgene picked up the slack.

The legacy Bristol-Myers business had some hematology expertise of its own—and that’s something Celgene is already taking advantage of.

Amgen aims to prove its $13.4 billion Otezla pickup was worth it by revving up new indications and new international launches.

While we haven't seen anything like last year's megamerger so far in 2020, EY predicts M&A will remain strong this year.

Celgene last year inked a $55 million settlement over allegations it blocked multiple myeloma drug competition. Now, it's backing out.

Tidying up business left from last year, Bristol-Myers Squibb has completed the sale of an old-school operation in Italy.

Pfizer and BMS' Eliquis, Gilead's Truvada and hundreds of other branded medicines have higher prices after Jan. 1.